medigraphic.com

2012, Number 1

<< Back Next >>

Rev Cuba Endoc 2012; 23 (1)

Somatostatin analogues in the treatment of diabetic retinopathy

Maciques RJE, Pérez MME, Hernández YA, Santana PF, Licea PME

Language: Spanish
References: 37
Page:
PDF size: 50.41 Kb.


ABSTRACT

The diabetic retinopathy is an important health problem due to visual disability provoked. The choice treatment still remains the laser photocoagulation, but sometimes there is advanced ways in which the response is poor and the course is torpid. Other alternatives of treatment are look for to improve the course including the steroids and anti-angiogenic. The aim of present review was to regroup the current information on this group of drugs (somatostatin analogues), which has a anti-angiogenic effect and used in the treatment of proliferative diabetic retinopathy and the diabetic macular edema. The somatostatin analogues have shown to be effective, mainly in the control of hemorrhagic and proliferative phenomena and to also improve the integrity of the hematoretinal barrier, offer an alternative of treatment for diabetic macular edema, mainly when the response to laser is not favorable.


REFERENCES

  1. Reichlin S. Somatostatin (Review). N Engl J Med. 1983;309:1495-501.

  2. Pastor JC. Hipofisectomía. Capítulo 13. En: JC Pastor Jimeno. Retinopatía diabética: Barcelona; Editorial JIMS SA; 1982. p. 191-6.

  3. Murube J, Agilar J, Cardona P. Palomar A. Epidemiología y causas de Retinopatia Diabética. Arch Soc Canar Oftal. 1982;7:11-22.

  4. Lunbaeck K, Malmros R, Anderson RC. Hypophysectomy for diabetic retinopathy: a controlled trial. In: Golberg ME, Fine SL (eds.) Symposium on the treatment of diabetic retinopathy. Virginia. Washington DC: Government Printing Office. Airlie House. Warrington; 1969. p. 291-311.

  5. Shulkes A. Somatostatin: physiology and clinical applications. Baillieres Clin Endocrinol Metab. 1994;8:215-36.

  6. Oberg K. Future aspects of somatostatin-receptor mediated therapy. Neuroendocrinology. 2004;80:57-61.

  7. Melmed S. Structure of Somatostatin receptors in growth hormone control. Journal of Endocrinology. 1997;155:53-6.

  8. Reisine T, Bell GI. Molecular biology of Somatostatin receptors. Endocrine Reviews. 1995;16(4):427-42.

  9. Simó R, García-Ramirez, Carrasco E, Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabet Rev. 2006;2:71-98.

  10. Cantón A, Martínez-Cáceres EM, Hernández C, Espejo C, García-Arumí J, Simó R. CD4/CD8 and CD28 expression in T cells infiltrating the vitreous fl uid in diabetic patients with proliferative diabetic retinopathy: a flow cytometric analysis. Arch Ophthalmol. 2004;122:743-9.

  11. Simó R, Lecube A, Sararols L, García-Arumí J, Segura RM, Casamitjana R, et al. Deficit of somatostatin-like immunoreactivity in the vitreous fl uid of diabetic patients: possible role in the development of proliferative diabetic retinopathy. Diabetes Care. 2002;25:2282-6.

  12. Lamberts SWJ. A guide to the clinical use of somatostatin analogue SMS 201-995 (Sandostatin). Acta Endocrinol (Copenh). 1987;286:54-66

  13. Astorga-Jiménez R. Análogos de la somatostatina: perspectivas actuales y futuras. Med Clin (Barcelona). 1989;93:508-15.

  14. Bauer W, Briner U, Doepfner W. A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31:1133-40.

  15. Eriksson B, Öberg K. Sumario de 15 años de tratamiento de los tumores neuroendocrinos con análogos de la somatostatina y perspectivas futuras. Ann Oncol. 1999;8:28-36.

  16. Caron P, Cogne M, Gusthiot-Joudet B, Wakim S, Catus F, Bayard F. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of ocreotide (SMS 201-995). Eur J Endocrinol. 1995;132:320-5.

  17. Davis MI, Wilson SH, Grant MB. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors. Horm Metab Res. 2001;33:295-9.

  18. Craig A. Acromegaly. Drugs. 1994;47:425-45.

  19. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin. Molecular and Cellular Endocrinology. 2008;286:230-7.

  20. Chansson P, Timsit J, Harris G. Clinical pharmacokinetics of octreotide. Clinical Pharmacokinetics. 1993;25:375-91.

  21. Chassard D, Barbanoj M, Català M, Hawkins F, Moreiro J. Pharmacokinetics of Lanreotide. J Endocrinol Invest. 1997;20(supp17):30-2.

  22. Caron P. Somatuline® autogel®, une nouvelle forme galénique dans le traitement de l'acromégalie. Ann Endocrinol. 2002;3:2S19-2S24.

  23. Grant MB, Caballero S, Smith LEH. Somatostatin in diabetic eye disease. In: The Expanding Role of Octreotide II: Advances in Endocrinology and Eye Diseases. Eds. SWJ Lamberts and E Ghigo. Bristol: BioScientifica Ltd.; 2002. p. 165-84.

  24. Carrasco E, Hernández C, Miralles A, Huguet P, Farrés J, Simó R. Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care. 2007;30:2902-8.

  25. Plewe G, Noelken G, Krause U, Beyer J, del Pozo E. Suppression of growth hormone and somatomedin C by long-acting somatostatin analog SMS 201-995 in type I diabetes mellitus. Horm Res. 1987;27:7-12.

  26. Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. Acta Endocrinol (Copenh). 1989;120:187-94.

  27. Amann J, Kaven C, Spraul CW, Lang GK, Lang GE. Effect of octreotide combined with growth factors on proliferation of RPE cells in vitro. Ophthalmology. 2000;97:737-41.

  28. Grant MB. Caballero S. The potential role octreotide in the treatment of diabetic retinopathy. Treat Endocrinol. 2005;4(4):199-203.

  29. Palii SS, Caballero S Jr, Shapiro G, Grant MB. Medical treatment of diabetic retinopathy with somatostatina analogues. Expert Opin Investig Drugs. 2007;16:73-82.

  30. Croxen R, Baarsma GS, Kuijpers RW, Van Hagen PM. Somatostatin in diabetic retinopathy. Pediatr Endocrinol Rev. 2004;1(3):518-24.

  31. Boehm BO. Use of long-acting somatostatin analogue treatment in diabetic retinopathy. Dev Ophthalmol. 2007;39:111-21.

  32. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-De Hoff R, Caballero S, Estes KS. The efficacy of octreotide in the therapy of severe; nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000;23:504-9.

  33. Pareja A, López A, Mantolan C, Cordovés L, Serrano MA. Tratamiento con octreotide de la retinopatía diabética avanzada. Arch Soc Canar Oftal. 2002;13:235-7.

  34. Simo R, Carrasco E, Fonollosa A, Garcia-Arumi J, Casamitjana R, Hernandez C. Deficit of Somatostatin in the vitreous fluid of patients with diabetic macular. Diabetes Care. 2007;30:725-7.

  35. Kuijpers RW, Baarsma GS, Van Hagen PM. Treatment of cystoid macular edema with octreotide. N Engl J Med. 1998;338(9):624-6.

  36. Lang GE. Pharmacological treatment of diabetic retinopathy. Ophthalmologica. 2007;221:112-7.

  37. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res. 2001;33:300-6.




2020     |     www.medigraphic.com